Labcorp Holdings Inc. (LH) Stock Analysis and Metrics

Labcorp Holdings

NYSE: LH

$276.51 ▼ -0.30 (-0.11%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.10 Bn

P/E2.23

P/S0.15

Div. Yield0.11

ROIC (Qtr)0.00

Total Debt (Qtr)6.33 Bn

Revenue Growth (1y) (Qtr)5.75

Add ratio to table…

About

Labcorp ® Holdings Inc. is a global leader in laboratory services, delivering critical diagnostic insights and drug development capabilities to healthcare providers, pharmaceutical companies, researchers, and patients. Operating in the diagnostics and biopharmaceutical laboratory services industry, the company performs over 750 million tests annually, supporting clinical decision-making and accelerating innovations in healthcare. With nearly 71,000 employees across approximately 100 countries, Labcorp ® Holdings Inc. plays a pivotal role in advancing global health through science, technology, and operational excellence.

The company generates revenue primarily through diagnostic testing and biopharma laboratory services. Its Diagnostics Laboratories segment offers routine and specialty testing, including clinical, genetic, and anatomic pathology services, catering to physicians, hospitals, health systems, and patients. The Biopharma Laboratory Services segment provides drug development support, including central laboratory services, early-phase research, and companion diagnostics, serving pharmaceutical, biotechnology, and medical device companies. Revenue is derived from fee-for-service arrangements, capitation agreements, and direct payments from third-party payers, government programs, and patients.

The company operates through the following segments:

• Diagnostics Laboratories (Dx): This segment delivers a comprehensive menu of routine and specialty testing services through an integrated network of primary and specialty laboratories in the U. S. and Canada. It supports over 175 million patient encounters annually, offering clinical, genetic, genomic, and anatomic pathology tests, as well as occupational, wellness, and toxicology testing. The segment also provides digital pathology solutions, provider and payer digital platforms, and patient-facing applications to enhance accessibility and clinical decision-making.

• Biopharma Laboratory Services (BLS): This segment serves pharmaceutical, biotechnology, and medical device companies with end-to-end drug development support, including early-phase research, central laboratory services, and companion diagnostics. BLS operates a global network of laboratories and supports approximately 85% of new FDA-approved drugs and therapeutic products. The segment specializes in lead optimization, safety assessment, clinical trial enablement, and biomarker testing, leveraging advanced data analytics and technology-enabled solutions.

Labcorp ® Holdings Inc. holds a dominant position in the diagnostics and biopharma laboratory services industry, competing favorably against a fragmented market of hospital-based, physician-office, and independent laboratories. The company’s competitive advantages include its extensive test portfolio, national and global scale, advanced data and analytics capabilities, and leadership in high-growth specialty areas such as oncology, women’s health, autoimmune disease, and neurology. Its integrated service and logistics network, coupled with investments in digital pathology and artificial intelligence, further strengthen its market position. The company’s ability to support over 85% of FDA-approved drugs underscores its critical role in drug development and precision medicine.

The company serves a diverse customer base, including physicians, hospitals, health systems, managed care organizations, government healthcare programs, and patients. Its Biopharma Laboratory Services segment caters to hundreds of pharmaceutical, biotechnology, medical device, and contract research organizations, ranging from multinational corporations to emerging companies. Additionally, Labcorp ® Holdings Inc. engages directly with consumers through its Labcorp OnDemand platform, offering health and wellness testing services.

Investment Thesis

▲ Bull case

Labcorp's expansion of the DPYD Genotyping test to cover all AMP-recommended Tier 1 and Tier 2 variants positions the company as a critical enabler of safer oncology care, directly addressing a significant unmet clinical need. This initiative builds on Labcorp's established leadership in pharmacogenomics, where it has offered DPYD testing since 2006, and aligns with evolving clinical guidelines from NCCN and CPIC that recommend DPYD testing before fluoropyrimidine chemotherapy. By identifying patients at risk for severe toxicity from 5-FU and capecitabine—drugs used in treating colorectal, pancreatic, breast, and other cancers—Labcorp not only enhances patient safety but also strengthens its oncology portfolio, which is a key growth driver. The test's availability through Labcorp's national network ensures broad accessibility, and given that approximately 9% of patients carry actionable DPYD variants, this expansion could drive meaningful incremental test volume and revenue, particularly as oncology testing continues to grow at double-digit rates. This strategic move underscores Labcorp's ability to monetize scientific innovation in high-value specialty areas, where higher reimbursement and pricing power support margin expansion, a factor the market may be underestimating amid broader diagnostics growth narratives.
The collaboration with Epic to integrate Labcorp's full test menu into the Aura platform represents a transformative operational and accessibility advantage that is not fully reflected in current financial guidance. By eliminating the need for costly, time-consuming IT interfaces and embedding Labcorp's diagnostics directly into Epic's workflow—used by the majority of U.S. hospitals and health systems—this integration reduces friction for clinicians, accelerates test ordering, and improves turnaround times. This is particularly valuable as health systems face mounting pressure to streamline operations and improve care coordination. The expanded access to Labcorp's entire portfolio, including specialty tests in oncology, neurology, and women's health, positions the company to capture increased volume from its largest customer segment. Moreover, the ability to rapidly deploy new tests (such as the DPYD genotyping or MyLabcorp-enabled offerings) within existing Epic workflows creates a scalable platform for innovation adoption. This strategic asset enhances Labcorp's competitive moat in the diagnostics space, supports long-term client retention, and could drive organic growth above current mid-single-digit expectations, especially as health systems prioritize vendors that offer seamless, interoperable solutions.
Labcorp's MyLabcorp app launch, enhanced with AI-powered features and clinical context, taps into a growing consumer demand for personalized health insights, with over half of consumers viewing AI as important for understanding healthcare information. The app's ability to combine lab results with AI-generated explanations, educational content, and pattern recognition over time addresses a critical gap in current consumer health tools, which often deliver isolated results without clinical guidance. By securing distribution in both the Apple App Store and Google Play Store and planning ongoing feature rollouts, Labcorp is building a direct-to-consumer channel that leverages its trusted brand and scientific expertise. This initiative extends beyond transactional testing to foster ongoing engagement, potentially increasing test frequency through preventive and wellness-oriented panels (e.g., men's and women's health, longevity, cancer screening). While currently a smaller segment, Consumer Health has demonstrated double-digit growth, and MyLabcorp's AI integration could accelerate adoption and monetization through premium offerings or data-driven insights. The market may be overlooking this as a long-term growth lever, focusing instead on traditional B2B dynamics, but the shift toward consumer-driven healthcare presents a durable opportunity for Labcorp to expand its addressable market and deepen customer relationships.

Labcorp's expansion of the DPYD Genotyping test to cover all AMP-recommended Tier 1 and Tier 2 variants positions the company as a critical enabler of safer oncology care, directly addressing a significant unmet clinical need. This initiative builds on Labcorp's established leadership in pharmacogenomics, where it has offered DPYD testing since 2006, and aligns with evolving clinical guidelines from NCCN and CPIC that recommend DPYD testing before fluoropyrimidine chemotherapy. By identifying patients at risk for severe toxicity from 5-FU and capecitabine—drugs used in treating colorectal, pancreatic, breast, and other cancers—Labcorp not only enhances patient safety but also strengthens its oncology portfolio, which is a key growth driver. The test's availability through Labcorp's national network ensures broad accessibility, and given that approximately 9% of patients carry actionable DPYD variants, this expansion could drive meaningful incremental test volume and revenue, particularly as oncology testing continues to grow at double-digit rates. This strategic move underscores Labcorp's ability to monetize scientific innovation in high-value specialty areas, where higher reimbursement and pricing power support margin expansion, a factor the market may be underestimating amid broader diagnostics growth narratives.
The collaboration with Epic to integrate Labcorp's full test menu into the Aura platform represents a transformative operational and accessibility advantage that is not fully reflected in current financial guidance. By eliminating the need for costly, time-consuming IT interfaces and embedding Labcorp's diagnostics directly into Epic's workflow—used by the majority of U.S. hospitals and health systems—this integration reduces friction for clinicians, accelerates test ordering, and improves turnaround times. This is particularly valuable as health systems face mounting pressure to streamline operations and improve care coordination. The expanded access to Labcorp's entire portfolio, including specialty tests in oncology, neurology, and women's health, positions the company to capture increased volume from its largest customer segment. Moreover, the ability to rapidly deploy new tests (such as the DPYD genotyping or MyLabcorp-enabled offerings) within existing Epic workflows creates a scalable platform for innovation adoption. This strategic asset enhances Labcorp's competitive moat in the diagnostics space, supports long-term client retention, and could drive organic growth above current mid-single-digit expectations, especially as health systems prioritize vendors that offer seamless, interoperable solutions.
Labcorp's MyLabcorp app launch, enhanced with AI-powered features and clinical context, taps into a growing consumer demand for personalized health insights, with over half of consumers viewing AI as important for understanding healthcare information. The app's ability to combine lab results with AI-generated explanations, educational content, and pattern recognition over time addresses a critical gap in current consumer health tools, which often deliver isolated results without clinical guidance. By securing distribution in both the Apple App Store and Google Play Store and planning ongoing feature rollouts, Labcorp is building a direct-to-consumer channel that leverages its trusted brand and scientific expertise. This initiative extends beyond transactional testing to foster ongoing engagement, potentially increasing test frequency through preventive and wellness-oriented panels (e.g., men's and women's health, longevity, cancer screening). While currently a smaller segment, Consumer Health has demonstrated double-digit growth, and MyLabcorp's AI integration could accelerate adoption and monetization through premium offerings or data-driven insights. The market may be overlooking this as a long-term growth lever, focusing instead on traditional B2B dynamics, but the shift toward consumer-driven healthcare presents a durable opportunity for Labcorp to expand its addressable market and deepen customer relationships.

▼ Bear case

Labcorp's reliance on the Biopharma Laboratory Services (BLS) segment for margin expansion masks underlying fragility in the Early Development (ED) business, where organic growth remains stagnant despite strategic actions. The company reported flat ED revenue in Q1 FY26, with organic constant currency growth of only 0.7%, and acknowledged that ED book-to-bill remains below 1.0 due to the short-cycle nature of the business, which depends on rapid project conversion. While management expects ED to strengthen in the second half of the year, this assumes a rebound in project wins that has not yet materialized, and the completion of strategic actions by Q2 FY26 may not immediately translate to revenue growth. The BLS segment's overall book-to-bill of 1.04 is buoyed by Central Labs (CLS), which trails at 1.0 on a TTM basis, but ED's weakness could drag down segment performance if CLS growth slows. Furthermore, the company's expectation that BLS margin will expand more than Diagnostics hinges on continued top-line growth in CLS and operating efficiencies in ED—both of which are uncertain. If ED fails to reaccelerate, the BLS segment's margin improvement may stall, undermining the enterprise's EPS growth guidance and revealing a dependency on a single high-growth pillar that is less diversified than portrayed.
The company's optimism regarding weather-related volume impacts appears inconsistent with its own operational reality, as it downplays the recapture rate of disrupted appointments despite admitting that 70% to 75% of its Diagnostics business flows through physician offices—where patient rescheduling is less controllable. Adam Schechter acknowledged that recapturing weather-affected requisitions is "a bit harder to go after" until they re-enter the system, implying a meaningful portion of lost volume may not be recovered. Yet, Julia Wang stated that the company does not bake in explicit weather assumptions for full-year guidance, treating it as a potential factor within the revenue range rather than a modeled risk. This approach ignores the increasing volatility of weather patterns and the potential for repeated disruptions, especially given that Q1 FY26 already saw a $15 million revenue impact from adverse conditions. If weather-related disruptions persist or intensify through the remainder of FY26, the cumulative effect could suppress organic volume growth below the guided 2.9% for Diagnostics, particularly since the company relies on organic growth as the primary driver of revenue and margin expansion. The market may be assuming weather impacts are transitory, but Labcorp's own commentary suggests structural challenges in recapturing lost volume from physician-office-based testing.
While Labcorp highlights its LaunchPad initiative as a driver of margin expansion through AI and robotics, the company provides no concrete timeline, capital allocation details, or measurable efficiency targets for these efforts, raising questions about their near-term impact. Adam Schechter described LaunchPad as a long-term effort to "reduce costs" and "improve customer experience" via technologies like digital pathology and AI-assisted billing, but Julia Wang attributed Q1 FY26's 30-basis-point margin expansion in Diagnostics primarily to organic growth—not operational efficiencies. This disconnect suggests that LaunchPad's benefits may be delayed or incremental, yet the company continues to cite it as a key support for full-year margin guidance. Furthermore, the investment in a new strategic facility to support Central Labs Services operations—cited as contributing to capex at ~4% of revenue—implies near-term capital intensity that could pressure free cash flow, despite the guided range of $1.24 billion to $1.36 billion. If LaunchPad fails to deliver timely cost savings or if the new facility incurs higher-than-expected ramp-up expenses, the enterprise's ability to achieve double-digit EPS growth could be jeopardized. The market may be pricing in margin expansion from these initiatives without sufficient evidence of near-term execution, creating a downside risk if operational improvements lag expectations.

Labcorp's reliance on the Biopharma Laboratory Services (BLS) segment for margin expansion masks underlying fragility in the Early Development (ED) business, where organic growth remains stagnant despite strategic actions. The company reported flat ED revenue in Q1 FY26, with organic constant currency growth of only 0.7%, and acknowledged that ED book-to-bill remains below 1.0 due to the short-cycle nature of the business, which depends on rapid project conversion. While management expects ED to strengthen in the second half of the year, this assumes a rebound in project wins that has not yet materialized, and the completion of strategic actions by Q2 FY26 may not immediately translate to revenue growth. The BLS segment's overall book-to-bill of 1.04 is buoyed by Central Labs (CLS), which trails at 1.0 on a TTM basis, but ED's weakness could drag down segment performance if CLS growth slows. Furthermore, the company's expectation that BLS margin will expand more than Diagnostics hinges on continued top-line growth in CLS and operating efficiencies in ED—both of which are uncertain. If ED fails to reaccelerate, the BLS segment's margin improvement may stall, undermining the enterprise's EPS growth guidance and revealing a dependency on a single high-growth pillar that is less diversified than portrayed.
The company's optimism regarding weather-related volume impacts appears inconsistent with its own operational reality, as it downplays the recapture rate of disrupted appointments despite admitting that 70% to 75% of its Diagnostics business flows through physician offices—where patient rescheduling is less controllable. Adam Schechter acknowledged that recapturing weather-affected requisitions is "a bit harder to go after" until they re-enter the system, implying a meaningful portion of lost volume may not be recovered. Yet, Julia Wang stated that the company does not bake in explicit weather assumptions for full-year guidance, treating it as a potential factor within the revenue range rather than a modeled risk. This approach ignores the increasing volatility of weather patterns and the potential for repeated disruptions, especially given that Q1 FY26 already saw a $15 million revenue impact from adverse conditions. If weather-related disruptions persist or intensify through the remainder of FY26, the cumulative effect could suppress organic volume growth below the guided 2.9% for Diagnostics, particularly since the company relies on organic growth as the primary driver of revenue and margin expansion. The market may be assuming weather impacts are transitory, but Labcorp's own commentary suggests structural challenges in recapturing lost volume from physician-office-based testing.
While Labcorp highlights its LaunchPad initiative as a driver of margin expansion through AI and robotics, the company provides no concrete timeline, capital allocation details, or measurable efficiency targets for these efforts, raising questions about their near-term impact. Adam Schechter described LaunchPad as a long-term effort to "reduce costs" and "improve customer experience" via technologies like digital pathology and AI-assisted billing, but Julia Wang attributed Q1 FY26's 30-basis-point margin expansion in Diagnostics primarily to organic growth—not operational efficiencies. This disconnect suggests that LaunchPad's benefits may be delayed or incremental, yet the company continues to cite it as a key support for full-year margin guidance. Furthermore, the investment in a new strategic facility to support Central Labs Services operations—cited as contributing to capex at ~4% of revenue—implies near-term capital intensity that could pressure free cash flow, despite the guided range of $1.24 billion to $1.36 billion. If LaunchPad fails to deliver timely cost savings or if the new facility incurs higher-than-expected ramp-up expenses, the enterprise's ability to achieve double-digit EPS growth could be jeopardized. The market may be pricing in margin expansion from these initiatives without sufficient evidence of near-term execution, creating a downside risk if operational improvements lag expectations.

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password